71 related articles for article (PubMed ID: 832968)
1. Oral vaccination and multivalent vaccine against Pseudomonas aeruginosa keratitis.
Gerke JR; Nelson JS
Invest Ophthalmol Vis Sci; 1977 Jan; 16(1):76-80. PubMed ID: 832968
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
3. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.
Kreger AS; Lyerly DM; Hazlett LD; Berk RS
Invest Ophthalmol Vis Sci; 1986 Jun; 27(6):932-9. PubMed ID: 3519522
[TBL] [Abstract][Full Text] [Related]
4. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
[TBL] [Abstract][Full Text] [Related]
5. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection.
Zaidi TS; Priebe GP; Pier GB
Infect Immun; 2006 Feb; 74(2):975-83. PubMed ID: 16428743
[TBL] [Abstract][Full Text] [Related]
6. Effector mechanisms of protection against Pseudomonas aeruginosa keratitis in immunized rats.
Thakur A; Kyd J; Xue M; Willcox MD; Cripps A
Infect Immun; 2001 May; 69(5):3295-304. PubMed ID: 11292752
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies provide protection against ocular Pseudomonas aeruginosa infection.
Moon MM; Hazlett LD; Hancock RE; Berk RS; Barrett R
Invest Ophthalmol Vis Sci; 1988 Aug; 29(8):1277-84. PubMed ID: 2843483
[TBL] [Abstract][Full Text] [Related]
8. [Oral application of bacterial vaccine for infection prophylaxis (author's transl)].
Seifert J; Urbach G; Lob G
Chir Forum Exp Klin Forsch; 1980; ():73-7. PubMed ID: 7389484
[TBL] [Abstract][Full Text] [Related]
9. [An oral enteritis-vaccine composed of twelve heat-inactivated Enterobacteriaceae 3. Communication: studies on efficacy tests in mice protection tests (author's transl)].
Raettig H
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1981 Nov; 250(4):511-20. PubMed ID: 7036591
[TBL] [Abstract][Full Text] [Related]
10. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
[TBL] [Abstract][Full Text] [Related]
11. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive.
Hazlett LD; McClellan S; Kwon B; Barrett R
Invest Ophthalmol Vis Sci; 2000 Mar; 41(3):805-10. PubMed ID: 10711697
[TBL] [Abstract][Full Text] [Related]
12. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
13. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Pier G
Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
[No Abstract] [Full Text] [Related]
15. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
Sourek J; Výmola F; Zelenková L
Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles.
Ito S; Nakamura J; Fukuta M; Ura T; Teshigawara T; Fukushima J; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 May; 39(23):3152-3160. PubMed ID: 33934918
[TBL] [Abstract][Full Text] [Related]
17. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
[TBL] [Abstract][Full Text] [Related]
18. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.
Worgall S; Kikuchi T; Singh R; Martushova K; Lande L; Crystal RG
Infect Immun; 2001 Jul; 69(7):4521-7. PubMed ID: 11401995
[TBL] [Abstract][Full Text] [Related]
19. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice.
Sokalska M; Maresz-Babczyszyn J
Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542
[TBL] [Abstract][Full Text] [Related]
20. Oral vaccination against Porteus mirabilis.
Jones RJ
Br J Exp Pathol; 1976 Aug; 57(4):395-9. PubMed ID: 822863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
